JAZZ

#794
Jazz Pharmaceuticals, Inc.
199.5850 USD
+2.19%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
199.3200
199.6500
Rango anual
128.8000
200.2400
Cambio diario
+2.19%
Variación mensual
+11.05%
Variación en los últimos 6 meses
+42.56%
Cambio anual
+42.56%
Cierres anteriores
195.3100
Abrir
199.5000
Bid
Ask
Mínimo
199.3200
High
199.6500
Volumen
97
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 12.2865 B
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-29.11
Relación precio/flujo de caja
2.43

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Noticias